Journal Article > CommentaryFull Text
E Clinical Medicine. 2021 June 1; Volume 36; 100911.; DOI:10.1016/j.eclinm.2021.100911
Batista C, Shoham S, Ergonul O, Hotez PJ, Bottazzi ME, et al.
E Clinical Medicine. 2021 June 1; Volume 36; 100911.; DOI:10.1016/j.eclinm.2021.100911
Journal Article > Meta-AnalysisFull Text
Int J Infect Dis. 2020 February 1; Volume 92; DOI:10.1016/j.ijid.2020.01.042
Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, et al.
Int J Infect Dis. 2020 February 1; Volume 92; DOI:10.1016/j.ijid.2020.01.042
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians and public health staff with an updated and easy-to-consult document arising from consensus of Global Tuberculosis Network (GTN) experts. The core published documents and guidelines have been reviewed including the recently published MDR-TB WHO rapid advice and ATS/CDC/ERS/IDSA guidelines. After a rapid review of epidemiology and risk factors, the clinical priorities on MDR-TB diagnosis (including whole genome sequencing and drug-susceptibility testing interpretations) and treatment (treatment design and management, TB in children) are discussed. Furthermore, the review comprehensively describes the latest information on contact tracing and LTBI management in MDR-TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB sequelae, infection control and other public health priorities.
Journal Article > CommentaryFull Text
E Clinical Medicine. 2021 June 1; Volume 36; 100925.; DOI:10.1016/j.eclinm.2021.100925
Naniche D, Hotez PJ, Bottazzi ME, Ergonul O, Figueroa J, et al.
E Clinical Medicine. 2021 June 1; Volume 36; 100925.; DOI:10.1016/j.eclinm.2021.100925
Journal Article > CommentaryFull Text
E Clinical Medicine. 2021 August 3; Volume 39; DOI:10.1016/j.eclinm.2021.101053
Hotez PJ, Batista C, Amor YB, Ergonul O, Figueroa J, et al.
E Clinical Medicine. 2021 August 3; Volume 39; DOI:10.1016/j.eclinm.2021.101053
A Lancet Commission for COVID-19 task force is shaping recommendations to achieve vaccine and therapeutics access, justice, and equity. This includes ensuring safety and effectiveness harmonized through robust systems of global pharmacovigilance and surveillance. Global production requires expanding support for development, manufacture, testing, and distribution of vaccines and therapeutics to low- and middle-income countries (LMICs). Global intellectual property rules must not stand in the way of research, production, technology transfer, or equitable access to essential health tools, and in context of pandemics to achieve increased manufacturing without discouraging innovation. Global governance around product quality requires channelling widely distributed vaccines through WHO prequalification (PQ)/emergency use listing (EUL) mechanisms and greater use of national regulatory authorities. A World Health Assembly (WHA) resolution would facilitate improvements and consistency in quality control and assurances. Global health systems require implementing steps to strengthen national systems for controlling COVID-19 and for influenza vaccinations for adults including pregnant and lactating women. A collaborative research network should strive to establish open access databases for bioinformatic analyses, together with programs directed at human capacity utilization and strengthening. Combating anti-science recognizes the urgency for countermeasures to address a global-wide disinformation movement dominating the internet and infiltrating parliaments and local governments.
Journal Article > CommentaryFull Text
PLOS Med. 2021 September 13; Volume 18 (Issue 9); e1003772.; DOI:10.1371/journal.pmed.1003772
Figueroa J, Hotez PJ, Batista C, Ergonul O, Gilbert S, et al.
PLOS Med. 2021 September 13; Volume 18 (Issue 9); e1003772.; DOI:10.1371/journal.pmed.1003772
Journal Article > CommentaryFull Text
E Clinical Medicine. 2022 January 1; Volume 43; 101230.; DOI:10.1016/j.eclinm.2021.101230
Batista C, Hotez PJ, Ben Amor Y, Kim JH, Kaslow D, et al.
E Clinical Medicine. 2022 January 1; Volume 43; 101230.; DOI:10.1016/j.eclinm.2021.101230